Iodide

Iodide

SCHEMBL1502780

CC(O)C[N+](C)(C)C.[I-]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL193840 0.97
SCHEMBL9748138 0.97
SCHEMBL9748670 0.97
Hydrochloric Acid SCHEMBL9748547 0.93
Water SCHEMBL22462356 0.93 MAPT (0.40)
Fluoride Ion SCHEMBL1502834 0.93
Water SCHEMBL11879378 0.93 MAPT (0.40)
Hydrochloric Acid SCHEMBL194776 0.93
Water SCHEMBL341614 0.93
Bromide SCHEMBL1502778 0.93

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017187245-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF APIXABAN OPTIMUS DRUGS (P) LIMITED (IN) 2017-11-02 WO claimed
US-20170313695-A1 PROCESS FOR THE PREPARATION OF APIXABAN OPTIMUS DRUGS PRIVATE LIMITED (IN) 2017-11-02 US claimed
US-6773822-B2 ANTIFUNGAL AGENT MAY BE PRESENT IN THE GYPSUM CORE AND/OR ON ONE OR BOTH OF THE PAPER FACINGS, AND MAY BE ENCAPSULATED IN A MATERIAL THAT RELEASES THE ANTIFUNGAL AGENT OVER TIME AND/OR UPON EXPOSURE TO MOISTURE. TEMPLE-INLAND FOREST PRODUCTS CORPORATION 2004-08-10 US claimed
US-20240084067-A1 NOVEL CURABLE COMPOSITION CONTAINING CYCLIC MONOMER TOKUYAMA CORPORATION (JP) 2024-03-14 US disclosed
EP-4286435-A1 NOVEL CURABLE COMPOSITION CONTAINING CYCLIC MONOMER Tokuyama Corporation (JP) 2023-12-06 EP disclosed
CN-114728255-A Microspheres containing ionic groups and method for producing same 株式会社德山 2022-07-08 CN disclosed
EP-3318543-B1 METHOD FOR PRODUCING ORGANIC COMPOUND M TECHNIQUE CO LTD (JP) 2021-11-17 EP disclosed
CN-110477861-A To ensure the sweat sensing in a manner of time sequencing UNIV CINCINNATI 2019-11-22 CN disclosed
CN-105916433-B Sweat sensing in a chronological manner 辛辛那提大学 2019-08-30 CN disclosed
US-10287232-B2 Method for producing an organic compound in a rotating forced thin-film microreactor M. TECHNIQUE CO., LTD. (JP) 2019-05-14 US disclosed
US-10077263-B2 Process for the preparation of Apixaban OPTIMUS DRUGS PRIVATE LIMITED (IN) 2018-09-18 US disclosed
US-20040087802-A1 Process for preparing glycidylphthalimide OSAKA SODA CO., LTD. (JP) 2004-05-06 US disclosed
EP-1403267-A1 Process for preparing glycidylphthalimide DAISO CO., LTD. (JP) 2004-03-31 EP disclosed
US-6680127-B2 COMPRISING AN ANTIFUNGAL AGENT AND A RETENTION AID, SUCH AS A SURFACTANT, IN ONE OR MORE PAPER FACINGS. TEMPLE-INLAND FOREST PRODUCTS, CORPORATION 2004-01-20 US disclosed
US-20030035981-A1 Antifungal gypsum board TIN INC. D/B/A TEMPLE-INLAND 2003-02-20 US disclosed
US-20030031898-A1 Antifungal gypsum board TIN INC. D/B/A TEMPLE-INLAND 2003-02-13 US disclosed
EP-0435068-B1 Process for producing optically active atenolol and intermediate thereof DAISO CO LTD (JP) 1995-03-29 EP disclosed
US-5223646-A Process for producing optically active atenolol and intermediate thereof DAISO COMPANY, LTD. (JP) 1993-06-29 US disclosed
US-5130482-A PROCESS FOR PRODUCING OPTICALLY ACTIVE ATENOLOL AND INTERMEDIATE THEREOF DAISO COMPANY, LTD. (JP) 1992-07-14 US disclosed
EP-0435068-A2 Process for producing optically active atenolol and intermediate thereof DAISO CO., LTD. (JP) 1991-07-03 EP disclosed